Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
FWBI First Wave BioPharma
5.430-0.250-4.40%
Close
01/27 16:00 ET
5.4300.0000.00%
Post Mkt Price 01/27 19:47 ET
High
5.820
Open
5.600
Turnover
2.37M
Low
5.200
Pre Close
5.680
Volume
431.61K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
HC Wainwright Reiterates "Buy" Rating for First Wave BioPharma (NASDAQ:FWBI)
First Wave BioPharma (NASDAQ:FWBI – Get Rating)'s stock had its "buy" rating restated by research analysts at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga
First Wave BioPharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/26/2023 226.09% HC Wainwright & Co. → $18 Reiterates → Buy 12/02/2022 -27.54% HC Wainwright & Co. $8 →
HC Wainwright & Co. Reiterates Buy on First Wave BioPharma
HC Wainwright & Co. analyst Yi Chen reiterates First Wave BioPharma with a Buy.
First Wave Target Adjusted to $18 for Stock Split at H.C. Wainwright
Why Grom Social Enterprises Shares Are Trading Lower By 30%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) shares surged 85% to $2.2200. Sonoma Pharmaceuticals and EMC Pharma announced Department of Defense DAPA registration for Microcyn(R) Rx products.Ens
GMBL, THMO and HLBZ Among Mid-day Movers
US Stocks Open Lower; Dow Dips 250 Points
U.S. stocks traded lower this morning, with the Dow Jones dropping around 250 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.74% to 33,484.47 while the NASDAQ fell
First Wave Surges ~30% on Patent Filing for Adrulipase's Delayed Release Formulation
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersSonoma Pharmaceuticals (NASDAQ:SNOA) stock rose 80.0% to $2.16 during Wednesday's pre-market session. The company's market cap stands at $6.7 million. First Wave BioPharma (NASDAQ:FWBI) stock m
First Wave BioPharma Announced Expansion of Adrulipase Intellectual Property Portfolio
First Wave BioPharma, Inc. (NASDAQ:FWBI) announced today the company has filed a U.S. Provisional Patent application involving composition of matter improvements designed to enhance adrulipase's del
Company Overview
More
First Wave Biopharma, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of non-systemic therapies for the treatment of gastrointestinal diseases. The firm involves in therapeutic development pipeline populated with multiple clinical stage programs built around its proprietary technologies, such as Niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Its programs include FW-UP, FW-UC, FW-CD,FW-COV, FW-ICI-AC, MS1819, COVID-19 GI infections, and FW-EPI. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.
CEO： Mr. James Sapirstein
Market： NASDAQ
Listing Date： 10/11/2016
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet